SNSE
Sensei Biotherapeutics, Inc.
$13.00
+20.48%
$17.4M
No data for this timeframe.
Vol
Market Cap$17.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders13 funds
Inst. Value$24.1M
Inst. Activity4 buys / 0 sells
Insider Activity8B / 10S
Insider Net $-$756.6K
SEC Reports12
Recent Activity
Jun 10, 2026
SEC
Sensei Biotherapeutics filed Amendment No. 2 to its S-3 shelf registration to register 24,868,028 common shares for resa
S-3/A — Impact 4/10
Jun 10, 2026
SEC
Sensei Biotherapeutics filed an 8-K reporting the results of its June 10, 2026 annual meeting. Stockholders approved the
8-K — Impact 3/10
Jun 10, 2026
Insider
Gerry Christopher was granted 220,000 shares
President & PEO
Jun 10, 2026
Insider
Donenberg Phillip B. was granted 12,500 shares
Director
Jun 10, 2026
Insider
Holmen Bob was granted 12,500 shares
Director
Jun 2, 2026
SEC
Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (Business) in response
10-K/A — Impact 3/10
Inst.
Woodline Partners LP — NEW
361,010 shares ($11.4M)
Inst.
BANK OF AMERICA CORP — DOUBLED
33,025 shares ($1.0M)
Price Targets
$52.50
+303.8% upside
Strong Buy
Current $13.00
Low $50.00
Median $52.50
High $55.00
4 analysts
$50.00
$55.00
Analyst Ratings
4Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | BTIG | INITIATE | Buy |
| May 29, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| May 28, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy |
| May 22, 2026 | Citigroup | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-5.45 ▼ -712.8% | $-10.07 — $-0.98 | -39% YoY | 4 |
| Next Q | $-5.67 ▼ -687.4% | $-10.44 — $-1.00 | -57% YoY | 4 |
| Current FY | $-104.31 ▼ -3665.6% | $-161.01 — $-20.08 | -524% YoY | 4 |
| Next FY | $-7.90 ▼ -109.6% | $-13.86 — $-3.97 | 92% YoY | 4 |
Latest Reports
NEUTRAL
S-3/A
4/10
Sensei Biotherapeutics filed Amendment No. 2 to its S-3 shelf registration to register 24,868,028 common shares for resa
Jun 10, 2026
NEUTRAL
8-K
3/10
Sensei Biotherapeutics filed an 8-K reporting the results of its June 10, 2026 annual meeting. Stockholders approved the
Jun 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Woodline Partners LP | $11.4M | NEW |
| FRANKLIN RESOURCES INC | $4.2M | — |
| MARSHALL WACE, LLP | $2.1M | — |
| GOLDMAN SACHS GROUP INC | $1.9M | — |
| BANK OF AMERICA CORP | $1.0M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Gerry Christopher | A | $0.00 |
| Jun 10, 2026 | Donenberg Phillip | A | $0.00 |
| Jun 10, 2026 | Holmen Bob | A | $0.00 |
| Jun 1, 2026 | Cambrian BioPharma | SELL | $490.5K |
| Jun 1, 2026 | Peyer James | SELL | $490.5K |
13 institutional holders with $24.1M total value (822,608 shares) as of 2026-Q1. Top holders: Woodline, FRANKLIN, MARSHALL. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Woodline Partners LP | 361,010 | $11.4M | 47.2% | NEW |
| 2 | FRANKLIN RESOURCES INC | 133,506 | $4.2M | 17.5% | — |
| 3 | MARSHALL WACE, LLP | 65,730 | $2.1M | 8.6% | — |
| 4 | GOLDMAN SACHS GROUP INC | 61,568 | $1.9M | 8.1% | — |
| 5 | BANK OF AMERICA CORP /DE/ | 33,025 | $1.0M | 4.3% | DOUBLED +10692.5% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 32,041 | $1.0M | 4.2% | DOUBLED +178.2% |
| 7 | Brevan Howard Capital Management LP | 20,333 | $640.9K | 2.7% | — |
| 8 | FRED ALGER MANAGEMENT, LLC | 18,337 | $578.0K | 2.4% | — |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 16,205 | $510.8K | 2.1% | — |
| 10 | MORGAN STANLEY | 8,795 | $277.2K | 1.2% | DOUBLED +87850.0% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 7,750 | $244.3K | 1.0% | — |
| 12 | VANGUARD FIDUCIARY TRUST CO | 6,307 | $198.8K | 0.8% | — |
| 13 | HRT FINANCIAL LP | 58,001 | $1.8K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Woodline Partners LP | NEW | — | 361,010 | — | $11.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 306 | 33,025 | +10692.5% | $1.0M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 11,516 | 32,041 | +178.2% | $1.0M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 10 | 8,795 | +87850.0% | $277.2K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 631 | 306 | -51.5% | $3.3K | 2025-Q4 |
| UBS Group AG | TRIM | 2,140 | 873 | -59.2% | $8.3K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2 | 42,541 | +2126950.0% | $16.8K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 215,572 | 156,800 | -27.3% | $76.8K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 258 | 136 | -47.3% | $67.00 | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 15,366 | 66,044 | +329.8% | $39.5K | 2024-Q3 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 10,000 | 45,575 | +355.8% | $27.3K | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 139 | 258 | +85.6% | $154.00 | 2024-Q3 |
7 unique insiders with 24 transactions. Net insider value: -$756.6K ($500.0K bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Gerry Christopher | President & PEO | AWARD | 220,000 | — | — |
| Jun 10, 2026 | Donenberg Phillip B. | Director | AWARD | 12,500 | — | — |
| Jun 10, 2026 | Holmen Bob | Director | AWARD | 12,500 | — | — |
| Jun 1, 2026 | Cambrian BioPharma Inc | 10%+ Owner | SELL | 24,524 | $20.00 | $490.5K |
| Jun 1, 2026 | Peyer James | 10%+ Owner | SELL | 24,524 | $20.00 | $490.5K |
| Apr 10, 2026 | Donenberg Phillip B. | Director | AWARD | 23,100 | — | — |
| Apr 10, 2026 | Craver Josiah | PFO & PAO | AWARD | 80,000 | — | — |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 1,108 | $33.38 | $37.0K |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 2,115 | $28.94 | $61.2K |
| Apr 6, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 1,214 | $31.02 | $37.7K |
| Apr 6, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 1,104 | $31.02 | $34.2K |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 3,099 | $30.86 | $95.6K |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 26 | $33.47 | $870.23 |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 1,161 | $31.53 | $36.6K |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 1,104 | $31.52 | $34.8K |
| Mar 31, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 191 | $24.28 | $4.6K |
| Mar 31, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 616 | $24.69 | $15.2K |
| Mar 30, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 518 | $25.85 | $13.4K |
| Mar 30, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 2,992 | $25.08 | $75.0K |
| Mar 27, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 469 | $26.77 | $12.6K |
| Mar 27, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 10,643 | $26.29 | $279.8K |
| Mar 26, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | SELL | 583 | $26.88 | $15.7K |
| Mar 26, 2026 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | BUY | 778 | $27.23 | $21.2K |
| Feb 13, 2026 | Donenberg Phillip B. | Director | AWARD | 1,900 | — | — |
12 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 8 neutral. Avg impact: 4.4/10.
NEUTRAL
S-3/A
4/10
Sensei Biotherapeutics filed Amendment No. 2 to its S-3 shelf registration to register 24,868,028 co
Jun 10, 2026
NEUTRAL
8-K
3/10
Sensei Biotherapeutics filed an 8-K reporting the results of its June 10, 2026 annual meeting. Stock
Jun 10, 2026
NEUTRAL
10-K/A
3/10
Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (B
Jun 2, 2026
BEARISH
S-3/A
6/10
Sensei Biotherapeutics filed an S-3/A to register up to 24,868,028 shares of common stock for resale
Jun 2, 2026
BEARISH
CLUSTER
7/10
Two 10% owners of Sensei Biotherapeutics sold a combined $981K in open-market sales at $20/share, re
Jun 1, 2026
NEUTRAL
DEFA14A
3/10
Sensei Biotherapeutics filed a DEFA14A supplement to its definitive proxy statement, updating board
May 22, 2026
NEUTRAL
8-K
2/10
Sensei Biotherapeutics filed an 8-K disclosing that director nominee Karen Vousden requested a delay
May 22, 2026
NEUTRAL
DEFA14A
5/10
Sensei Biotherapeutics filed a DEFA14A proxy supplement providing unaudited pro forma financials for
May 21, 2026
NEUTRAL
8-K
4/10
Sensei Biotherapeutics reported Q1 2026 results showing a net loss of $170.2M ($131.45/share), prima
May 15, 2026
BEARISH
144
5/10
Cambrian BioPharma Inc., a 10% stockholder of Sensei Biotherapeutics, filed a Form 144 on April 29,
Apr 29, 2026
BEARISH
S-3
6/10
Sensei Biotherapeutics filed an S-3 registration statement to register up to 24,868,028 shares of co
Apr 28, 2026
NEUTRAL
DEFA14A
5/10
Sensei Biotherapeutics filed additional definitive proxy materials urging stockholders to vote FOR a
Apr 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 4 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$52.50 mean target
+303.8% upside
Strong Buy (1.00)
$50.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $13.00 |
| Target Low | $50.00 |
| Target Mean | $52.50 |
| Target Median | $52.50 |
| Target High | $55.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-5.45 | $-10.07 | $-0.98 | -39.3% | -712.8% | — | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-5.67 | $-10.44 | $-1.00 | -56.6% | -687.4% | — | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-104.31 | $-161.01 | $-20.08 | -523.8% | -3665.6% | — | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-7.90 | $-13.86 | $-3.97 | 92.4% | -109.6% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-5.446 | |
| 7d ago | $-3.905 | -1.541 |
| 30d ago | $-0.670 | -4.776 |
| 60d ago | $0.000 | -5.446 |
| 90d ago | $0.000 | -5.446 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | BTIG | INITIATE | — | Buy |
| May 29, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| May 28, 2026 | LUCID CAPITAL MARKETS | INITIATE | — | Buy |
| May 22, 2026 | Citigroup | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
交易直播 #KNRX：这图一眼就别买（和#SNSE同一个陷阱）
▲ 1
💬 0
⚡ 0.0
交易直播 #KNRX：这图一眼就别买（和#SNSE同一个陷阱）
▲ 1
💬 0
⚡ 0.0
May 4, 2026
earnings_calendar
SNSE Q1 2026 Earnings Scheduled — 2026-05-04
Mar 26, 2026
earnings_calendar
SNSE Q4 2025 Earnings After Market Close — 2026-03-26
Mar 16, 2026
short_interest
FTD: SNSE — 26,041 shares ($0.8M) failed to deliver
Settlement: 20260316, Price: $32.28, FTD Value: $840,603.48, SENSEI BIOTHERAPEUTICS INC COM
Mar 11, 2026
short_interest
FTD: SNSE — 17,191 shares ($0.5M) failed to deliver
Settlement: 20260311, Price: $30.00, FTD Value: $515,730, SENSEI BIOTHERAPEUTICS INC COM
Feb 20, 2026
short_interest
FTD: SNSE — 22,842 shares ($0.6M) failed to deliver
Settlement: 20260220, Price: $27.22, FTD Value: $621,759.24, SENSEI BIOTHERAPEUTICS INC COM
Feb 19, 2026
short_interest
FTD: SNSE — 73,294 shares ($1.9M) failed to deliver
Settlement: 20260219, Price: $26.25, FTD Value: $1,923,967.5, SENSEI BIOTHERAPEUTICS INC COM